Immunotherapy for gastric premalignant lesions and cancer

Immunotherapy

Volumn 4, Issue 6, 2012, Pages 587-599

  Zorzetto, Valerio ^a   Maddalo, Gemma ^b   Basso, Daniela ^c   Farinati, Fabio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

atrophic gastritis; autoimmune gastritis; carcinoid; gastric cancer; gastrin 17; Helicobacter pylori; interleukin; Th17; Treg; vaccination

Indexed keywords

CISPLATIN; CYTOKINE; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID G17; FLUOROURACIL; FOLINIC ACID; GASTRIN; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC ATROPHIC GASTRITIS; DISEASE ASSOCIATION; ENTEROCHROMAFFIN CELL; GASTRITIS; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; STOMACH CANCER; STOMACH CARCINOID; STOMACH LESION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; ENTEROCHROMAFFIN-LIKE CELLS; GASTRINS; GASTRITIS, ATROPHIC; HUMANS; IMMUNOTHERAPY; PRECANCEROUS CONDITIONS; RISK; STOMACH NEOPLASMS;

EID: 84863893252     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.50     Document Type: Review

References (123)

1. Filipe M, Munoz N, Matko I et al. Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia. Int. J. Cancer 57(3), 324-329 (1994
2. Sipponen P, Riihela M, Hyvärinen H et al. Chronic nonatrophic ('superficial') gastritis increases the risk of gastric carcinoma. A case-Control study. Scand. J. Gastroenterol. 29(4), 336-340 (1994
3. Correa P. The biological model of gastric carcinogenesis. IARC Sci. Publ. 157, 301-310 (2004
4. Rugge M, Correa P, Dixon MF et al. Gastric mucosal atrophy: INTEROBSERVER consistency using new criteria for classification and grading. Aliment. Pharmacol. Ther. 16(7), 1249-1259 (2002
5. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process - first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52, 6735-6740 (1992
6. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 20, 1161-1181(1996
7. Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 29(7), 671-678 (1997
8. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: A tutorial. Dig. Liver Dis. 40(8), 650-658 (2008
9. Genta R. Gastritis on the stage. Adv. Anat. Pathol. 14(3), 233(2007
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
11. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-Called intestinal-Type carcinoma. An attempt at a histo-Clinical classification. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965
12. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-Term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525-1528 (1995
13. Miwa H, Go MF, Sato N. Helicobacter pylori and gastric cancer: The Asian enigma. Am. J. Gastroenterol. 97, 1106-1112 (2002
14. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol. Biomarkers Prev. 15, 1083-1094 (2006
15. de Vries AC, Meijer GA, Looman CW et al. Epidemiological trends of premalignant gastric lesions: A long-Term nationwide study in The Netherlands. Gut 56(12), 1665-1670 (2007
16. Ohata H, Kitauchi S, Yoshimura N et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 109, 138-143(2004
17. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 2, 58-60 (1975
18. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori. A combined analysis of 12 case control studies nested within prospective cohorts. Gut 49, 347-353(2001
19. Rugge M, Cassaro M, Di Mario F et al. Interdisciplinary Group on Gastric Epithelial Dysplasia (IGGED): The long-Term outcome of gastric non-Invasive neoplasia. Gut 52(8), 1111-1116 (2003
20. Yamaoka Y. Mechanisms of disease: HELICOBACTER pylori virulence factors. Nat. Rev. Gastroenterol. Hepatol. 7(11), 629-641(2010
21. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: FACTORS that modulate disease risk. Clin. Microbiol. Rev. 23(4), 713-739 (2010
22. Basso D, Zambon CF, Letley DP et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 135(1), 91-99 (2008
23. Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. Helicobacter pylori babA2, cagA, and s1vacA genes work synergistically in causing intestinal metaplasia. J. Clin. Pathol. 56(4), 287-291(2003
24. Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. Hum. Immunol. 72, 1128-1136 (2011
25. Forones NM, Mandowsky SV, Lourenco LG. Serum levels of interleukin-2 and tumor necrosis factor-Alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 48, 1199-1201(2001
26. Izutani R, Katoh M, Asano S, Ohyanagi H, Hirose K. Enhanced expression of manganese superoxide dismutase mRNA and increased TNF-Alpha mRNA expression by gastric mucosa in gastric cancer. World J. Surg. 20, 228-233(1996
27. Machado JC, Pharoah P, Sousa S et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121, 823-829 (2001
28. Rad R, Dossumbekova A, Neu B et al. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 53, 1082-1089 (2004
29. El-Zimaity HM, Ota H, Graham DY et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 94, 1428-1436 (2002
30. Hsing AW, Hansson LE, McLaughlin JK et al. Pernicious anemia and subsequent cancer: A population-Based cohort study. Cancer 71, 745-750 (1993
31. Annibale B, Azzoni C, Corleto VD et al. Atrophic body gastritis patients with enterochromaffin-Like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur. J. Gastroenterol. Hepatol. 13, 1449-1456 (2001
32. Bordi C. Gastric carcinoids. Ital. J. Gastroenterol. Hepatol. 31(Suppl. 2), S94-S97 (1999
33. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch. Intern. Med. 156, 1097-1100 (1996
34. Modlin IM, Lye KD, Kidd M. A 50 year analysis of 562 gastric carcinoids: Small tumor or larger problem? Am. J. Gastroenterol. 99, 23-32 (2004
35. Dakin GF, Warner RR, Pomp A et al. Presentation, treatment, and outcome of type gastric carcinoid tumors. J. Surg. Oncol. 93(5), 368-372 (2006
36. Hosokawa O, Kaizaki Y, Hattori M et al. Long-Term follow-up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 8, 42-46 (2005
37. Berna MJ, Annibale B, Marignani M et al. A prospective study of gastric carcinoids and enterochromaffin-Like cell changes in multiple endocrine neoplasia type 1and Zollinger-Ellison syndrome: IDENTIFICATION of risk factors. J. Clin. Endocrinol. Metab. 93, 1582-1591(2008
38. Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: Their production and biological activities. Annu. Rev. Physiol. 63, 119-139 (2001
39. Waldum HL, Kleveland PM, Brenna E et al. Interactions between gastric acid secretagogues and the localization of the gastrin receptor. Scand. J. Gastroenterol. 44(4), 390-393(2009
40. Zhang L, Ozao J, Warner R. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J. Surg. 35, 1879-1886 (2011
41. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340, 930-932 (1992
42. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch. Intern. Med. 156, 1097-1100 (1996
43. Wang TC, Dangler CA, Chen D et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118, 36-47 (2000
44. Dickson JH, Grabowska A, El-Zaatari M, Atherton J, Watson SA. Helicobacter pylori can induce heparin-Binding epidermal growth factor expression via gastrin and its receptor. Cancer Res. 66, 7524-7531(2006
45. Kidd M, Tang LH, Modlin IM et al. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia. Digestion 62, 143-151(2000
46. Cui G, Takaishi S, Ai W et al. Gastrin-Induced apoptosis contributes to carcinogenesis in the stomach. Lab. Invest. 86, 1037-1051(2006
47. Przemeck SM, Varro A, Berry D et al. Hypergastrinemia increases gastric epithelial susceptibility to apoptosis. Regul. Pept. 146, 147-156 (2008
48. Sun WH, Zhu F, Chen GS et al. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett. 263, 302-311(2008
49. Pritchard DM, Berry D, Przemeck SM, Campbell F, Edwards SW, Varro A. Gastrin increases mcl-1expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G798-G805 (2008
50. Wroblewski LE, Pritchard DM, Carter S, Varro A. Gastrin-Stimulated gastric epithelial cell invasion: The role and mechanism of increased matrix metalloproteinase 9 expression. Biochem. J. 365, 873-879 (2002
51. Noble PJ, Wilde G, White MR, Pennington SR, Dockray GJ, Varro A. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G75-G84 (2003
52. Camargo MC, Mera R, Correa P et al. Interleukin-1beta and interleukin-1receptor antagonist gene polymorphisms and gastric cancer: A meta-Analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1674-1687 (2006
53. Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ. Association of interleukin-1gene polymorphisms with gastric cancer: A meta-Analysis. Int. J. Cancer 120, 552-562 (2006
54. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1RN polymorphisms and gastric carcinoma risk: A meta-Analysis. J. Gastroenterol. Hepatol. 25, 1604-1617 (2010
55. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk - a meta-Analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1920-1928 (2006
56. Hwang IR, Kodama T, Kikuchi S et al. Effect of interleukin 1polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 123(6), 1793-1803(2002
57. Zambon CF, Basso D, Navaglia F et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine 18(5), 242-251(2002
58. Chakravorty M, Datta De D, Choudhury A, Roychoudhury S. IL1B promoter polymorphism regulates the expression of gastric acid stimulating hormone gastrin. Int. J. Biochem. Cell Biol. 41(7), 1502-1510 (2009
59. Beales IL. Effect of interlukin-1beta on proliferation of gastric epithelial cells in culture. BMC Gastroenterol. 2, 7 (2002
60. Beales IL, Calam J. Interleukin 1beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 42(2), 227-234 (1998
61. Datta De D, Bhattacharjya S, Maitra M et al. IL1B induced Smad 7 negatively regulates gastrin expression. PLoS ONE 6(3), e14775 (2011
62. Chakravorty M, Datta De D, Choudhury A, Roychoudhury S. IL1B promoter polymorphism regulates the expression of gastric acid stimulating hormone gastrin. Int. J. Biochem. Cell Biol. 41(7), 1502-1510 (2009
63. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu. Rev. Physiol. 63, 49-76 (2001
64. Chan AO, Chu KM, Huang C et al. Association between Helicobacter pylori infection and interleukin 1beta polymorphism predispose to CpG island methylation in gastric cancer. Gut 56(4), 595-597 (2007
65. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-Analyses. Am. J. Epidemiol. 173(3), 259-270 (2011
66. Matsuo K, Oka M, Murase K et al. Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J. Int. Med. Res. 31, 69-75 (2003
67. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12, 33-40 (2001
68. Klampfer L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets 11, 451-464 (2011
69. Berger FG. The interleukin-6 gene: A susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res. Treat. 88, 281-285 (2004
70. Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J. Gastroenterol. 16, 1188-1200 (2010
71. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 7, 22-33(2005
72. Vetvicka V, Vetvickova J. Procathepsin D and cytokines influence the proliferation of lung cancer cells. Anticancer Res. 31, 47-51(2011
73. Xie JY, Li MX, Xiang DB et al. Elevated expression of APE1/Ref-1and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma. Clin. Lymphoma Myeloma Leuk. 10, 385-393(2010
74. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 55, 241-269 (2003
75. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int. J. Cancer 104, 617-623(2003
76. Zhang J, Dou C, Song Y et al. Polymorphisms of tumor necrosis factor-Alpha are associated with increased susceptibility to gastric cancer: A meta-Analysis. J. Hum. Genet. 53(6), 479-489 (2008
77. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology (7th Edition). Elsevier/Saunders, Philadelphia, USA (2012
78. D'Elios MM, Benagiano M, Della Bella C, Amedei A. T-Cell response to bacterial agents. J. Infect. Dev. Ctries 5(9), 640-645 (2011
79. Moudgil KD, Choubey D. Cytokines in autoimmunity: Role in induction, regulation, and treatment. J. Interferon Cytokine Res. 31(10), 695-703(2011
80. Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-Tolerance and autoimmune disease. Immunol. Rev. 212, 8-27 (2006
81. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-Tolerance. Cell 101, 455-458 (2000
82. Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci. 1(1), 20 (2011
83. Mosmann TR, Coffman RL. TH1and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173(1989
84. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 383(6603), 787-793(1996
85. Jetten AM. Immunology: A helping hand against autoimmunity. Nature 472(7344), 421-422 (2011
86. Stockinger B, Veldhoen M, Martin B. Th17 T cells: Linking innate and adaptive immunity. Semin. Immunol. 19(6), 353-361(2007
87. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361(9), 888-898 (2009
88. Ghoreschi K, Laurence A, Yang XP et al. Generation of pathogenic T(H)17 cells in the absence of TGF b signalling. Nature 467(7318), 967-971(2010
89. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8(4), 345-350 (2007
90. Callaghan JM, Khan MA, Alderuccio F, van Driel IR, Gleeson PA, Toh BH. Alpha and beta subunits of the gastric H+/K+-ATPase are concordantly targeted by parietal cell autoantibodies associated with autoimmune gastritis. Autoimmunity 16(4), 289-295 (1993
91. Karlsson FA, Burman P, Loof L, Mardh S. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H,K-Adenosine triphosphatase of the stomach. J. Clin. Invest. 81, 475-479 (1988
92. Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Pre-Differentiated Th1and Th17 effector T cells in autoimmune gastritis: AG-Specific regulatory T cells are more potent suppressors than polyclonal regulatory T cells. Int. Immunopharmacol. 9(5), 540-545 (2009
93. Stummvoll GH, DiPaolo RJ, Huter EN et al. Th1, Th2, and Th17 effector T cell-Induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J. Immunol. 181(3), 1908-1916 (2008
94. Onishi N, Yuasa H, Tanaka S et al. Transgenic expression of Helicobacter pylori CaA-Induces gastrointestinal and hematopoietic neoplasma in mouse. Proc. Natl Acad. Sci. USA 105, 1003-1008 (2008
95. Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J. Physiol. Pharmacol. 60(3), 3-21(2009
96. D'Elios MM, Manghetti M, De Carli M et al. T helper 1effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. 158(2), 962-967 (1997
97. Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter. Helicobacter 1, 21-28 (2010
98. Faller G, Winter M, Steininger H et al. Decrease of antigastric autoantibodies in Helicobacter pylori gastritis after cure of infection. Pathol. Res. Pract. 195, 243-246 (1999
99. D'Elios MM, Bergman MP, Amedei A, Appelmelk BJ, Del Prete G. Helicobacter pylori and gastric autoimmunity. Microbes Infect. 6(15), 1395-1401(2004
100. D'Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and cytokines: The 'dangerous liaisons'. FEMS Immunol. Med. Microbiol. 44(2), 113-119 (2005
101. Blanchard TG, Czinn SJ. Review article: IMMUNOLOGICAL determinants that may affect the Helicobacter pylori cancer risk. Aliment. Pharmacol. Ther. 1, 83-90 (1998
102. Iwamoto S, Kido M, Aoki N et al. IFN-G is reciprocally involved in the concurrent development of organ-Specific autoimmunity in the liver and stomach. Autoimmunity 45(2), 186-198 (2012
103. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-Like receptors: Regulating the regulators. Ann. Rheum. Dis. 66(3), 91-95 (2007
104. Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Järbrink M. CD4+CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur. J. Immunol. 37(1), 282-291(2007
105. Maruyama T, Kono K, Mizukami Y et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-Infiltrating lymphocytes, tumor-Draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 101(9), 1947-1954 (2010
106. Henwood M, Clarke PA, Smith AM, Watson SA. Expression of gastrin in developing gastric adenocarcinoma. Br. J. Surg. 88, 564-568 (2001
107. Hur K, Kwak MK, Lee HJ et al. Expression of gastrin and its receptor in human gastric cancer tissues. J. Cancer Res. Clin. Oncol. 132, 85-91(2006
108. Watson SA, Morris TM, Varro A, Michaeli D, Smith AM. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: Relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 45, 812-817 (1999
109. Gilliam AD, Watson SA, Henwood M et al. A Phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol. 30, 536-543(2004
110. Ajani JA, Randolph Hecht J, Ho L et al. An open-Label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-Fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study. Cancer 106, 1908-1916 (2006
111. Watson SA, Michaeli D, Grimes S et al. Gastrimmune raises antibodies that neutralise amidated and glycine-Extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 56, 880-885 (1996
112. Watson SA, Michaeli D, Grimes S et al. A comparison of an anti-Gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice. Int. J. Cancer 81(2), 248-254 (1999
113. WHO Classification of Tumours of the Digestive System (4th Edition). Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds). International Agency for Research on Cancer, Lyon, France (2010
114. Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract. Res. Clin. Gastroenterol. 19(5), 659-673(2005
115. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg. Oncol. 12, 153-172 (2003
116. Campana D, Nori F, Pezzilli R et al. Gastric endocrine tumors type I: Treatment with long-Acting somatostatin analogs. Endocr. Relat. Cancer 15(1), 337-342 (2008
117. Tieppo C, Betterle C, Basso D et al. Gastric type I carcinoid: A pilot study with human G17DT immunogen vaccination. Cancer Immunol. Immunother. 60(7), 1057-1060 (2011
118. Eto M, Kamiryo Y, Takeuchi A et al. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin. Cancer Res. 14, 2833-2840 (2008
119. Petrausch U, Jensen SM, Twitty C et al. Disruption of TGF-Beta signaling prevents the generation of tumor-Sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 183, 3682-3689 (2009
120. Van Den Engel NK, Rüttinger D, Rusan M et al. Combination immunotherapy and active-Specific tumor cell vaccination augments anti-Cancer immunity in a mouse model of gastric cancer. J. Transl. Med. 9, 140 (2011
121. Amedei A, Niccolai E, D'Elios MM. T cells and adoptive immunotherapy: Recent developments and future prospects in gastrointestinal oncology. Clin. Dev. Immunol. 2011, 320571(2011
122. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57, 443-478 (1988
123. Amedei A, Benagiano M, Della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J. Biomed. Biotechnol. 2011, 437348 (2011)